Category Archives: HLA Protein Technologies Inc.

HLA Protein Technologies Debuts sHLA-G Monomer and Tetramer Portfolio for High-Fidelity Checkpoint Biology, Target Validation, and Assay Development

OKLAHOMA CITY, Okla., Nov. 19, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools.

HLA Protein Technologies, Inc. (formerly Pure Protein, LLC)
Image caption: HLA Protein Technologies, Inc.

HLA-G PORTFOLIO HIGHLIGHTS

The Company’s broad new sHLA-G platform includes biotinylated monomers, fluorophore-labeled tetramers, and peptide-loaded complexes, produced using a proprietary mammalian expression system to ensure authentic folding, natural glycosylation, and physiologically relevant epitope presentation.

These reagents enable high-throughput screening, antibody validation, and translational research applications such as:

  • Drug discovery and immune checkpoint studies
  • Diagnostic assay development (ELISA, BLI, SPR)
  • Transplantation and autoimmunity research

HLA-G BIOLOGY AND RESEARCH IMPACT

HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator. Its unique tolerogenic properties and restricted polymorphism make it critical for studies in immune tolerance, transplantation, oncology, autoimmunity, and infectious disease. Soluble isoforms of HLA-G exert powerful immunosuppressive effects, influencing NK cells, T cells, B cells, and dendritic cells – critical pathways for therapeutic development.

DEDICATED FOCUS ON HLA PROVIDES VALUE TO RESEARCHERS

  • Accelerated R&D: Ready-to-use, biologically accurate HLA reagents can accelerate project timelines.
  • World-Class Data Quality: Native-like sHLA-G molecules yield more predictive and reproducible results than non-soluble HLA.
  • Translational Confidence: sHLA closely reflects human biology, bridging the gap between bench research and clinical application.
  • Regulatory Readiness: Standardized, validated products support compliance and documentation for therapeutic development.

“Our sHLA-G portfolio marks a breakthrough for advancing next-generation immunotherapies, enabling researchers to decode and harness HLA-G–mediated immune regulation in cancer and transplantation.,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “By combining biological fidelity with scalable production, we’re providing tools that accelerate discovery and clinical translation.”

AVAILABILITY

The sHLA-G product line is now available for order at https://www.hlaprotein.com/products/hla-class-i/hla-g.

Custom projects and collaborations are supported through dedicated technical and licensing teams.

ABOUT HLA PROTEIN TECHNOLOGIES, INC.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high-purity HLA proteins, engineered cell lines and custom assay development.

With a focus on immunology and oncology, the company provides HLA-based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.


This press release was issued on behalf of the news source (HLA Protein Technologies Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-debuts-shla-g-monomer-and-tetramer-portfolio-for-high-fidelity-checkpoint-biology-target-validation-and-assay-development/

Copr. © 2025 Send2Press® Newswire, Calif., USA. -- REF: S2P STORY ID: S2P131138 NOREL-3B

 

HLA Protein Technologies Announces Next-Gen HLA Product Lines and Strategic Investment

OKLAHOMA CITY, Okla., Sept. 30, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools.

HLA Protein Technologies, Inc. (formerly Pure Protein, LLC)
Image caption: HLA Protein Technologies, Inc.

The new investment will fund accelerated product development and expanded manufacturing capacity at the company’s Oklahoma City headquarters, with additional hiring across R&D, bioprocess and commercial operations. HLA Protein Technologies will scale production capacity, implement expanded QC/QA frameworks and enhance GMP‑adjacent processes suitable for research‑use‑only (RUO) products.

The company expects to add roles across protein biochemistry, cell biology, manufacturing operations and commercial support. Facility enhancements will prioritize throughput, reproducibility and documentation standards to align with customer expectations in biopharma R&D.

And, the rebrand to HLA Protein Technologies unifies the company’s legacy of protein engineering with its expanded mission: delivering best‑in‑class HLA research tools and services to customers across biopharma, diagnostics and translational research. This transition establishes a brand identity that mirrors the company’s core scientific strengths and customer value proposition in HLA‑based research tools. The new name and visual identity will roll out across product labels, documentation and digital properties over the coming weeks.

“This is a pivotal moment in our company’s evolution,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “Our new HLA portfolio pairs rigorously characterized reagents with custom services that help biopharma teams accelerate target discovery and validation, immune monitoring and mechanism‑of‑action studies. The rebrand reflects our commitment to leadership in HLA‑enabled solutions.”

Anchored by two decades of expertise in soluble HLA engineering and peptide–MHC technologies, the new product lines will feature next‑generation Class I and Class II HLA tetramers, new product formats and custom peptide‑loaded complexes designed for high‑throughput discovery, screening and translational studies.

This portfolio will be complemented by custom assay development and engineered cell line services to support biopharma and academic partners advancing immunotherapies and vaccine research. These new products will complement the Company’s existing portfolio of more than 275 HLA Class I and Class II alleles; it will be made available to the scientific community at https://hlaprotein.com/.

“Oklahoma’s life sciences ecosystem is gaining momentum, and HLA Protein Technologies’ growth exemplifies that trajectory,” said Michelle Gregory, Director, Life Science Oklahoma. “The company’s expansion and investment in local manufacturing aligns with our mission to advance U.S.-based innovation and bioproduction.”

About HLA Protein Technologies, Inc.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high‑purity HLA proteins, engineered cell lines and custom assay development. With a focus on immunology and oncology, the company provides HLA‑based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.


This press release was issued on behalf of the news source (HLA Protein Technologies Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-announces-next-gen-hla-product-lines-and-strategic-investment/

Copr. © 2025 Send2Press® Newswire, Calif., USA. -- REF: S2P STORY ID: S2P129731 NOREL-3B